Home | About the eMC | Help | Mobile

eMC - trusted, up to date and comprehensive information about medicines

Search medicine/company name only

Search full document

Advanced search

Medicine name A-Z | Active ingredient A-Z | Pharmaceutical company A-Z | Latest medicine updates | Yellow card report

Chemidex Pharma Ltd

Chemidex House, Egham Business Village, Crabtree Road, Egham, Surrey, TW20 8RB

Telephone: +44 (0)1784 477 167
Fax: +44 (0)1784 471 776
WWW: http://www.chemidex.co.uk
Medical Information e-mail: info@chemidex.co.uk

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?

Summary of Product Characteristics last updated on the eMC: 19/01/2009

SPC	MUCOGEL SUSPENSION

Table of Contents

1. NAME OF THE MEDICINAL PRODUCT
2. QUALITATIVE AND QUANTITATIVE COMPOSITION
3. PHARMACEUTICAL FORM
4. CLINICAL PARTICULARS
4.1 Therapeutic indications
4.2 Posology and method of administration
4.3 Contraindications
4.4 Special warnings and precautions for use
4.5 Interaction with other medicinal products and other forms of interaction
4.6 Pregnancy and lactation
4.7 Effects on ability to drive and use machines
4.8 Undesirable effects
4.9 Overdose
5. PHARMACOLOGICAL PROPERTIES
5.1 Pharmacodynamic properties
5.2 Pharmacokinetic properties
5.3 Preclinical safety data
6. PHARMACEUTICAL PARTICULARS
6.1 List of excipients
6.2 Incompatibilities
6.3 Shelf life
6.4 Special precautions for storage
6.5 Nature and contents of container
6.6 Special precautions for disposal and other handling
7. MARKETING AUTHORISATION HOLDER
8. MARKETING AUTHORISATION NUMBER(S)
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
10. DATE OF REVISION OF THE TEXT

Go to top of the page

1. NAME OF THE MEDICINAL PRODUCT

MUCOGEL SUSPENSION

Go to top of the page

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each 5ml dose contains:

Aluminium Hydroxide Gel	220mg
BP
Magnesium Hydroxide BP	195mg

Go to top of the page

3. PHARMACEUTICAL FORM

Antacid suspension for oral administration.

Go to top of the page

4. CLINICAL PARTICULARS

Go to top of the page

4.1 Therapeutic indications

Antacid therapy in gastric and duodenal ulcer, gastritis, heartburn, gastric hyperacidity. Treatment of indigestion. Relief of symptoms of heartburn and dyspepsia associated with gastric reflux in hiatus hernia, reflux oesophagitis and similar conditions.

Go to top of the page

4.2 Posology and method of administration

Adults, elderly and children over 12 years of age:

10-20ml three times daily 20 minutes to one hour after meals, and at bedtime, or as required.

Children under 12 years of age:

Not recommended.

Go to top of the page

4.3 Contraindications

Should not be used in patients who are severely debilitated or suffering from kidney failure.

Go to top of the page

4.4 Special warnings and precautions for use

None stated.

Go to top of the page

4.5 Interaction with other medicinal products and other forms of interaction

Antacids inhibit the absorption of tetracyclines and vitamins and should not be taken concomitantly.

Go to top of the page

4.6 Pregnancy and lactation

For Mucogel Suspension no clinical data on exposed pregnancies are available.

Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development.

Caution should be exercised when prescribing to pregnant women.

Go to top of the page

4.7 Effects on ability to drive and use machines

None stated.

Go to top of the page

4.8 Undesirable effects

Gastrointestinal side-effects are uncommon. This formulation minimises the problems of diarrhoea and constipation.

Go to top of the page

4.9 Overdose

Serious symptoms are unlikely to follow overdosage.

Go to top of the page

5. PHARMACOLOGICAL PROPERTIES

Go to top of the page

5.1 Pharmacodynamic properties

The product contains two established antacids, magnesium and aluminium hydroxides with an acid neutralising capacity in excess of 25ml of 0.1N HC1 consumed, per gram of suspension.

Go to top of the page

5.2 Pharmacokinetic properties

Not applicable.

Go to top of the page

5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.

Go to top of the page

6. PHARMACEUTICAL PARTICULARS

Go to top of the page

6.1 List of excipients

Sorbitol Solution 70%

Mannitol